FEB 2 2 2005 Docket No. PRD-50USNF

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Chen, et al.

Serial No.: 10/688,572

Art Unit: 1625

Filed

: October 17, 2003

Examiner: Reyes, H.M.

For

: TREATING SYNDROME X WITH SUBSTITUTED TETRALINS AND

INDANES

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

2-17-05 (Pate of Percent)

Jeremy K. McKown (Name of applicant, assignee, or Registered Representative)

(Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on April 9, 2004.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In acc	cordance	MICH 8	1.129 (a)	, C	IIIS IIIIO	Imacion	
Disclosure State	ement is l	being	filed in	n co	nnection	with [] the
first or □secon	d After I	Final	Submissi	ion,	therefo	re:	
	Statement	in Ad	ccordanc	e wi	th §1. 97	(e)	
	(attached); or					
	Please ch	arge I	Deposit	Acco	ount No.	10-	
(0750/	/	the fee	of	\$180.00	as set	forth
:	in §1. 17(p).					

In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or an
action that otherwise closes prosecution and that it is
accompanied by one of:

		Statement in Accordance with §1.97(e)
		(attached); or
		Please charge Deposit Account No. 10-
		0750/PRD50USNP/JKM the fee of $$180.00$ as set
		forth in §1.17(p).
	☐ In a	ccordance with §1.97(d), this Information
Discl	losure Stat	tement is being filed after the mailing date of
eithe	er a Final	Action under §1.113 or a Notice of Allowance
under	§1.311 b	ut before the payment of the Issue Fee.
Appli	icant(s) he	ereby petition(s) for consideration of this
Info	rmation Dis	sclosure Statement. Included are: Statement in
Acco	rdance wit	h $\S 1.97$ (e) as set forth below and the fee of
\$180.	.00 as set	forth in §1.17(p).
	5 7	as a second of the reference listed on the
- 4-4		es of each of the references listed on the
		PTO-1449 are not enclosed. Please see Serial No
10/68	38,379 for	references.
	☐ Copi	es of references listed on the attached Form PTO
1449	are enclo	sed herewith EXCEPT THAT:
		In view of the voluminous nature of references
		[list as appropriate], and the likelihood that
•		these references are available to the Examiner,
		copies are not enclosed herewith.
		If any of the foregoing publications are not
		available to the Examiner, Applicant will
		endeavor to supply copies at the Examiner's
		request.
	□ Copi	es of only foreign patent documents and non-
patei		ure are enclosed in accordance with 37 CFR 1.98
_		U.S. patents and each U.S. patent application

publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i). There are no listed references which are not in the П English language. The relevance of those listed references which are \boxtimes not in the English language is as follows: WO02/28821 is listed in the IDS in German; however, I have attached the U.S. equivalent which is U.S. 6,750,236. Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD-50USNP/JKM. This form is submitted in triplicate. Respectfully submitted, Reg. No. 47,785 Attorney for Applicants Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-6250 DATED: 2/17/05 - 4 -

TRANSON THE Paperwork Reduction Act of 1995, no persons are required to respond to

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

a collection of information unless it displays a	a valid OMB control number.
Application Number	10/688,572
Filing Date	October 17, 2003
First Named Inventor	Chen, Xiaoli
Group Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	PRD-50-USNP

		Officer 1				
				U.S. PATENT DOCUMENTS		
Examiner Initials	Cite	U.S. Patent Document Kind Code ² Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		6,306,854	B1	Glaxosmithkline	10-23-2001	
		6,750,236	B2	Bayer Aktiengesellschaft	06-15-2004	
		(eq. to WO/02/28821)				
			<u> </u>			
			l			

FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, Date of Publication Foreign Patent Document of Cited Document where relevant Name of Patentee or passages or relevant T⁶ mm-dd-yyyy Examiner Cite Applicant of Cited Document figures appear KindCode⁵ Office³ Number⁴ No.1 06-25-1992 The Welcome Foundation WO 92/10468 A1 Ltd. 02-16-1995 Α1 The Upjohn Co. 95/04713 wo Glaxo Group Ltd. 10-09-1997 97/36579 A1 WO Bayer Aktiengesellschaft (U.S. eq. 04-11-2002 02/28821 **A2** WO 6,750,236) 08-22-2002 Pfizer Products Inc. wo 02/064549 **A1** 08-22-2002 02/064146 **A1** Aventis Pharma WO **Deutschland GMBH** 08-22-2002 Pfizer Products Inc. WO 02/064130 Α1

_			
			-1
-		Date	
	Examiner	Late	
		Considered	
	Signature		_
- 1	Signature	the state of the s	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not concept of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

a valid OMB CONSOCIATION
10/688,572
October 17, 2003
Chen, Xiaoli
1614
Not yet assigned
PRD-50-USNP

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	Γ
Examiner's	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
Milaio		ASSISMACOPOULOS-JEANNET, F. et al. "Effect of a peroxisome proliferator on β-oxidation and overall energy balance in obese (fa/fa) rats". Ame. Phy. Soc., 1991, pages R278 – R283	
		KLIEWER, S. A. et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome prolideratior-activated receptors α and γ." <u>Proc. Natl. Acad. Sci.</u> , 1997. Vol 94, pages 4318–4323.	
		CECCHI, R. et al., "Synthesis and β-adrenergic activity of atypical phenylethanolaminotetralin stereoisomers." <u>Eur. J. Med Chem.</u> 1994 , Vol. 29, pages 259-267.	
		BROWN, P. J. et al., "Generation of Secondary Alkyl Amines on Solid Support by Borane Reduction: Application to the Parallel Synthesis of PPAR Ligands", Synthesis, 1997, pages 778-782.	
		HAWKE, R. L., et al., "Potent pypocholesterolemic activity of novel ureido phenoxyisobutyrates correlates with their Intrinsic fibrate potency and not with their ACAT inhibitory activity." J. Lipid Res., 1997, Vol. 38, pages 1189-1203.	
		BROWN, P. J. et al., "Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library." <u>Chem. & Bio.</u> , 1997, Vol. 4, No. 12, pages 909-918.	
		BROWN, P. J., "A Ureido-Thioisobutyric Acid (GW9578) Is a Subtype-Selective PPAR α Agonist with Potent Lipid-Lowering Activity." J. Med. Chem., 1999, Vol. 42, pages 3785-3788.	
		GUERRE-MILLO, M. et al., "Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity." J. Bio. Chem., 2000, Vol. 275, No. 22, pages 16638-42.	
		BROWN, P. J., "Identification of a Subtype Selective Human PPAR a Agonist Through Parallel-Array Synthesis." Bioorg. Med. Chem. Lett., 2001, Vol. 11, pages 1225-1227.	
			1
	<u> </u>		
			1

Examiner	Date
	Considered
Signature 1	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Alexandria, VA 22331.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.